At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based CFO’ operating in the Health Diagnostics space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Christine A. Tsingos
EVP & CFO of Bio-Rad Laboratories
Ms. Christine A. Tsingos is Chief Financial Officer, Executive Vice President of Bio Rad Laboratories Inc. Previously, she was the Chief Operating Officer and Chief Financial Officer at Attest Systems, Inc., a provider of information technology asset discovery and management tools, from August 2002 to November 2002. Prior to that, Ms. Tsingos was a consultant to Attest Systems, Inc. from October 2000 to July 2002. She was the Chief Financial Officer at Tavolo, Inc., an online retailer of gourmet cookware and food, from November 1999 to September 2000, and she was Treasurer, and later Vice President and Treasurer, of Autodesk, Inc., a developer of design software, from May 1990 to November 1999.
Follow Christine A. Tsingos:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
CFO of Bio-Reference Laboratories
Follow Sam Singer:
About Bio-Reference Laboratories: BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing .
COO, CFO, CAO & Co-founder of Biocare Medical
Gene J. Castagnini, MS, MBA, co-founded Biocare Medical LLC in 1997 and serves as its Co-Owner and Chief Financial Officer. Gene Castagnini serves as the Chief Operating Officer and Executive Vice President of Biocare Medical, LLC Gene Castagnini served as the Chief Administrative Officer and Chief Financial Officer of BioGenex Laboratories. Inc., for 10 years. Gene Castagnini’s experience includes 15 years as a Director and Officer of Medi-Physics Inc., formerly a Hoffmann-La Roche Inc. subsidiary. Gene Castagnini has a BS in accounting and an MBA in Human Resource Management from the California State University school systems.
Follow Gene Castagnini:
About Biocare Medical: Biocare Medical is a provider of immunohistochemistry instrumentation.
CFO and Legal Counsel of Mojo Vision
Follow Brian Kinard:
About Mojo Vision: Mojo Vision is developing Mojo Lens, the world’s first AR smart contact lens with a built-in display that delivers Invisible Computing
Chief Financial Officer of Biohaven Pharmaceutical
Follow James Engelhart:
About Biohaven Pharmaceutical: Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
Chief Financial Officer of Bluebird Bio
William “Chip” Baird, joined bluebird in February of 2019 as chief financial officer. Chip has over 20 years of financial and strategic planning experience in the biopharmaceutical sector. Prior to bluebird, he served as CFO of Amicus Therapeutics for seven years and spent 10 years as CFO of PTC Therapeutics with responsibility for all areas of finance, investor and public relations, human resources, facilities and project management. Chip also worked in the life science practice at L.E.K. Consulting, a strategy consulting firm, and began his career at First Union National Bank in corporate debt underwriting. Chip received a B.S. from Georgetown University’s Edmund A. Walsh School of Foreign Service and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.
Follow William Baird:
About 2seventy bio, Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Senior Vice President Finance & Chief Financial Officer of Abbott
Brian Yoor is Senior Vice President Finance and Chief Financial Officer. He was appointed to his current position in June 2015. He previously served as Vice President, Investor Relations. Brian joined Abbott in August 1997, and held various financial management positions of increasing responsibility, including Controller positions in the pharmaceutical, nutrition, and diagnostic businesses, before being asked to lead Abbott’s Investor Relations effort in January 2013. Prior to joining Abbott, Brian was a certified public accountant with Arthur Andersen and held financial positions in the consumer industry with the Scotts Company and Newell Rubbermaid. “In Abbott Finance, we are the stewards that enable financial reliability and growth for Abbott, “ Says Brian. “ A strong, growing company is better able to help people around the world live their healthiest lives.” Brian serves on the board of the Clara Abbott Foundation. He is a member of NIRI, the National Investor Relations Institute. He earned his bachelor’s degree in accounting at the University of Toledo in Ohio.
Follow Brian Yoor:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Chief Financial Officer of Prevail Therapeutics
Brett Kaplan is our Chief Financial Officer. Prior to Prevail, he was Managing Director at Evercore, where he spent eight years concentrating on biopharma M&A and equity financings. Prior to Evercore, Brett was an Equity Research Analyst at Cowen, where he covered large cap pharmaceuticals. Earlier in his career, he held senior positions at Cubist and Lilly focused on corporate and business development. Brett holds an MBBCh and an MBA from the University of Witwatersrand in South Africa.
Follow Brett Kaplan:
About Prevail Therapeutics: Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Chief Financial Officer of ImmunityBio
In July 2019, ImmunityBio hired David Sachs as its Chief Financial Officer. As a finance, private equity, venture capital, and investment banking executive, he has over two decades of operational, development, and investing expertise. Sachs was formerly the CFO of various NantWorks companies, including NantHealth and Integrity Healthcare. He was also a principal and executive of NantCapital, where he sat on the investment committee. Sachs formerly worked as an investment banker for Bank of America Merrill Lynch and in senior operational roles at Abraxis BioScience and Celgene. He is now on the boards of Mox Networks, LLC, Packetfabric, Inc., and the Chan Soon-Shiong Medical Center at Windber. Sachs earned his MBA in Finance and Strategy from UCLA Anderson School of Management, as well as his BA in Economics from the University of California, Los Angeles.
Follow David Sachs:
About ImmunityBio, NantHealth: ImmunityBio is an offshoot of Soon-Shiong’s NantWorks conglomerate, developing molecular-level cell-based treatments for diseases.
Chief Financial Officer of Farcast
With over 20 years of experience in finance and accounting, Terry joined Farcast in 2019. As the CFO, he leads HR, Finance, IT, Legal, and Business Analytics. His past experience includes success in public accounting, turnaround management consulting, and most recently as CFO of a large manufacturing company. He holds undergraduate and graduate degrees from the University of Notre Dame as well as an MBA from the Kellogg School of Management at Northwestern University.
Follow Terry Brady:
About Farcast: Farcast develops a diagnostic platform that delivers powerful predictions for personalized cancer treatment selection and drug development.
Executive Vice President and Chief Financial Officer of Alere
James (“Jim”) Hinrichs joined Alere in April 2015 as Executive Vice President and Chief Financial Officer, with global responsibility for Finance, Accounting, Procurement, IT and Shared Services. Prior to his appointment as CFO of Alere, Jim Hinrichs was CFO at CareFusion Corp., a global medical technology corporation, since 2010. He held this position through the completion of Becton Dickinson’s acquisition of CareFusion in March 2015. Prior to this role, Hinrichs served as SVP of Global Customer Support and, before that, Corporate Controller of CareFusion. Previously, he was Executive Vice president and Controller of Cardinal Health, CFO of Cardinal Health’s Clinical and Medical Products segment and CFO of Cardinal Health’s Healthcare Supply Chain Services segment.. He joined Cardinal Health in February 2004, following 12 years of finance and marketing roles at Merck & Co. and two years as the CFO of SangStat Medical Corporation.
Follow James Hinrichs:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Chief Financial Officer of Genoa
Victor Breed is Genoa, a QoL Healthcare Company’s Chief Financial Officer. Breed joined Genoa in October 2006. Breed is responsible for accounting functions, treasury management, billing, purchasing, insurance/risk management and banking and investor relationships. He plays a significant role in raising equity financing and negotiating new bank financing. Previously Breed was the EVP of Finance and Operations for a medical device company, ClearMedical, Inc. As the EVP, Breed developed and implemented a new business model and managed all operational and administrative functions including production, engineering, regulatory, finance, accounting, human resources and IT. Prior to ClearMedical, Inc., Breed served as Senior Vice President for Solucient, LLC. While with Solucient, he was the General Manager of the business unit providing performance management solutions for hospitals. In addition, he identified and evaluated potential business partners and M&A candidates and negotiated business relationships, joint ventures and marketing arrangements. Before working for Solucient, LLC, Breed was the COO and CFO for HBS International. As COO/CFO Breed oversaw daily operations and developed strategies for accelerating growth by merger or acquisition. HBS International was one of the Deloitte & Touche Technology Fast 500; a list of the fastest growing technology companies in North America and on the 2000 Healthcare Informatics list of 10 Most Influential Healthcare IT Companies. Breed is a graduate of Lake Superior State University with a Bachelor of Science in Accounting. He is also a member of both the American Institute of Certified Public Accountants and the Washington Society of Certified Public Accountants.
Follow Victor Breed:
About Genoa: Genoa, a QoL Healthcare Company is the pharmacy and telepsychiatry provider serving the behavioral health and addiction treatment.
Chief Financial Officer of Sema4
Isaac Ro has 20 years of financial leadership and experience, with a strong focus on the medical technology and life sciences space. As Chief Financial Officer (CFO) at Sema4, Isaac is responsible for leading all aspects of financial strategy, management, and planning. Prior to joining Sema4, Isaac served as CFO of Thrive Earlier Detection Corp., a company dedicated to incorporating earlier detection of cancer into routine medical care. In this capacity, he led the sale of Thrive to Exact Sciences Corp. (Nasdaq: EXAS) for $2.15 billion after rapidly scaling the company and raising $257 million in a Series B financing. Before Thrive, Isaac led the U.S. Medical Technology team at Goldman Sachs where he covered the Life Science Tools, Diagnostics, and Medical Technology sectors. He also held a similar role at SVB Leerink. His career as an equity analyst spanned 16 years, over 60 publicly traded companies, and numerous IPOs and equity financing transactions. Isaac holds a B.A. in History and was pre-med at Middlebury College.
Follow Isaac Ro:
About Sema4: Sema4 uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.
Dan L. Dearen
President & Chief Financial Officer of Axonics Modulation Technologies
Follow Dan L. Dearen:
About Axonics Modulation Technologies: Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.
Senior Vice President and Chief Financial Officer of HiberCell
Joseph Talamo is the Senior Vice President and Chief Financial Officer at HiberCell.
Follow Joseph Talamo:
About HiberCell: HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.
Chief Financial Officer of Grail
Aaron Freidin is Chief Financial Officer at Grail.
Follow Aaron Freidin:
About Grail: Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
Chief Financial Officer of Seno Medical Instruments
Eric Davis is Chief Financial Officer of Seno Medical Instruments, Inc. Eric brings more than 26 years of financial and operational leadership with extensive domestic and international experience. He’s co-led several M&A efforts resulting in aggregate purchase prices over $500M and secured over $200M in investment capital. He’s a critical strategic thinker who also has the ability to define and implement at a tactical level. Eric was most recently the Chief Financial Officer of CeloNova BioSciences, Inc., a privately held medical device company who sold their Interventional Radiology/Oncology business to Boston Scientific at the end of 2015. Prior to CeloNova, Eric was the Chief Financial and Operating Officer at Genesis Networks Enterprises, LLC where he led the finance and accounting operations of a $1 billion network integrations and supply chain management company. Prior to Genesis, Eric spent time operating as senior finance and operations management in the Oil and Gas, Banking and Brokerage and Aero-Defense industries. Eric holds an MBA from Baylor University and BSBA in Management from the University of Tulsa. He’s also been inducted into the prestigious Beta Gamma Sigma honor society as a lifetime member and awarded Chartered Fellow (CMgr FCMI) by the Chartered Management Institute and Fellow Chartered Management Accountant (FCMA) and Chartered Global Management Accountant (CGMA) by the Chartered Institute of Management Accountants. He also holds certifications from Villanova University as a Certified Six Sigma Black Belt (CSSBB) and Certified Lean Six Sigma Sensei (CLSSS).
Follow Eric Davis:
About Seno Medical Instruments: Seno Medical is commercialization efforts in opto-acoustic imaging of breast cancer.
President Financial and Information Technology Services and CFO of Hackensack Meridian Health
Follow Robert Glenning:
About Hackensack Meridian Health: Hackensack Meridian Health is poised to better meet the needs of their communities.
Chief Financial Officer & Co-Founder of PetDx
Arthur Polk is the Chief Financial Officer and a Co-Founder at PetDx.
Follow Arthur Polk:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
Chief Financial Officer of Trak
Follow Paul Manners:
About Trak: Sandstone Diagnostics provides an integrated wellness technology that empowers consumers to measure, monitor, and improve their health.
Chief Financial Officer of Exact Sciences
Follow Jeff Elliot:
About Exact Sciences: Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Sr. Vice President & Chief Financial Officer of OPKO Health
Mr. Logal has served as OPKO’s Sr. Vice President and Chief Financial Officer since April 2014 and as OPKO’s Vice President of Finance, Chief Accounting Officer and Treasurer since March 2007. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. Mr. Logal currently serves on the board of directors of SciVac Therapeutics, Inc. (TSX: VAC), a commercial-stage biopharmaceutical company.
Follow Adam Logal:
About OPKO Health: Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.
Michael A. Doyle
Chief Financial Officer of Quanterix
With nearly 30 years of financial and management experience at major companies, Michael serves as Forrester’s chief financial officer (CFO). He leads Forrester’s finance team and oversees the company’s relationships with investors, market analysts, accountants, and bankers. Michael’s responsibilities also include both managing day-to-day financial activity as well as planning for Forrester’s long-term opportunities. Prior to joining Forrester, Michael was CFO of EasyLink Services, a publicly traded global telecommunications messaging provider. There he led an organization focused on improving productivity and financial planning and reporting. Previously, Michael served as CFO at Dun & Bradstreet, North America, responsible for driving the cash flow process improvement to record cash performance, and successfully integrating the Hoovers acquisition. Michael began his career at Continental Can where his tenure included financial management roles at the leading diversified packaging manufacturer. For the next 14 years, he held senior financial management positions at Cendant, Allied Signal, PepsiCo, as well as marketing and strategy positions at Cendant and PepsiCo. Michael holds a Master of Business Administration from New York University and a Bachelor of Business Administration in finance from the University of Notre Dame.
Follow Michael A. Doyle:
About Quanterix: Quanterix is a platform for single molecule analysis that supports clinical diagnostics, drug development, and life science researches.
CFO of Metamark Genetics
Mr. Cordo began his career in the life sciences industry in 1990. He held senior management positions in finance at Biogen Idec during his seven-year tenure where he put in place the financial infrastructure for the worldwide commercial launch of Avonex. For seven years, he was the Treasurer of Millennium Pharmaceuticals. At Millennium, he led finance teams in the raising of an $800 million follow-on equity offering and a $400 million convertible debt offering. He also led finance teams for three acquisitions. Dave has been interim chief financial officer for several venture capital backed life science companies, including Dicerna Pharmaceuticals, Epizyme, Inc., Link Medicine Corporation, TransForm Pharmaceuticals, Avila Therapeutics and Alinea Pharmaceuticals, and consulting on strategic financial issues for public and private life science companies. He is a Certified Public Accountant and holds an M.B.A. degree from Nichols College and a B.S.B.A. degree from Stonehill College. He is an active member of the Executive Committee of the Wake Forest University Parents’ Council and consults for several charitable organizations.
Follow David Cordo:
About Metamark Genetics, Novartis, Potenza Therapeutics, Semma Therapeutics: Metamark Genetics develops prognostic and predictive diagnostic tests that enable personalized treatment planning for cancer patients.
CFO of Helomics
Dane Saglio serves as Chief Financial Officer of Helomics®. Formerly, Mr. Saglio was the CFO of RegeneRx Biopharmaceuticals, Inc; SuperNova Diagnostics; New Generation Biofuels; EntreMed Biopharmaceuticals; and held senior financial positions with Sterling Software, Inc. and Public Communication Associates. Mr. Saglio also has extensive public and private company experience along with a wide range of corporate finance and strategic transactions experience. Dane earned his B.S. in business administration from the University of Maryland and is a licensed CPA (inactive).
Follow Dane Saglio:
About Helomics, RegeneRx: Helomics provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services.
Chief Financial Officer of SI-BONE
Laura A. Francis has served as our Chief Financial Officer since May 2015. Prior to joining SI BONE, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women’s health company, from December 2012 to September 2014. From September 2004 to December 2012, Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004, Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002, Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001, Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999, Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.
Follow Laura Francis:
About SI-BONE: SI-BONE advances the diagnostic understanding of lower back pain and minimally invasive surgery for the sacroiliac joint.
CFO & Co-Founder of Fluxergy
Jonathan Tu is the Chief Financial Officer and Co-Founder at Fluxergy.
Follow Jonathan Tu:
About Fluxergy: Fluxergy is a biotechnology company that offers point-of-care testing, PCR, and medical diagnostics.
CFO of Rev1 Ventures
Dave has responsibility for finance, operations, external reporting and human resources. He also serves as CFO for Rev1’s managed investment funds. Dave came to Rev1 after a career in corporate accounting with the holding company of Alamo, Enterprise and National Car Rental. He’s a skier and mountain biker, who is waiting for our entrepreneurs to invent the transporter so he can teleport back home to Montana for the weekends. Dave has a BS in Accounting from the University of Montana and is an Ohio licensed CPA.
Follow David Dillman:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Chief Financial Officer of Entrinsic Bioscience
Mario Wanderley is Managing Partner at VGP – Venture Growth Partners.
Follow Mario Wanderley:
About CitizenGlobal, Entrinsic Bioscience, Venture Growth Partners: Entrinsic Bioscience leverages gold standard science and game-changing amino acid technology.
Executive Vice President & CFO of Osi Systems
Alan Edrick is Executive Vice President and Chief Financial Officer of the Company. Alan joined the Company in this role in September 2006. Alan has more than two decades of financial management and public accounting experience, including mergers and acquisitions, capital markets, financial planning and analysis, and regulatory compliance. Between 2004 and 2006, Alan served as Executive Vice President and Chief Financial Officer of BioSource International, Inc., a biotechnology company, until its sale to Invitrogen Corporation. Between 1998 and 2004, Alan served as Senior Vice President and Chief Financial Officer of North American Scientific, Inc., a medical device and specialty pharmaceutical company. Between 1989 and 1998, Alan was employed by Price Waterhouse LLP in various positions including Senior Manager, Capital Markets. Alan received his Bachelor of Arts degree from the University of California, Los Angeles and a Master of Business Administration degree from the Anderson School at the University of California, Los Angeles.
Follow Alan Edrick:
About Osi Systems: OSI Systems is a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications.
Sr. Vice President & Chief Financial Officer of Beckman Coulter
Follow Knud Mueller:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
O. James Sterling
Chief Financial Officer of Renalytix AI
Follow O. James Sterling:
About Renalytix AI: RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
Claire M Gulmi
Chief Financial Officer & Executive Vice President of Secretary & Director of AmSurg Corporation
Claire M. Gulmi joined AMSURG in September 1994 as Vice President and Chief Financial Officer. Ms. Gulmi became Senior Vice President in March 1997, Secretary in December 1997, a Director in May 2004 and Executive Vice President in February 2006.
Follow Claire M Gulmi:
About AmSurg Corporation: AmSurg develops and operates ambulatory surgery centers.
CFO of Cambium Medical Technologies
Michael Broughton is CFO at Cambium Medical Technologies.
Follow Michael Broughton:
About Cambium Medical Technologies: CMT focuses on the development and commercialization of regenerative therapies derived from novel processed human platelets.
Chief Financial Officer of Sanguina
Rene Gonzalez is the chief financial officer at Sanguina.
Follow Rene Gonzalez:
About Sanguina: Sanguina is a wellness and diagnostic company offering at-home anemia management tools, through app technology and an over-the-counter kit.
VP & CFO of Galena Biopharma
Follow Ryan Dunlap:
About Galena Biopharma: Galena Biopharma, Inc. is focused on discovering, developing and commercializing innovative therapies.
Anthony M. Rimac
Chief Financial Officer of Cognoa
Follow Anthony M. Rimac:
About Cognoa: Cognoa is a behavioral health company focused on improving the lives and outcomes of children and families living with behavioral conditions
Chief Financial Officer of Alzheon
Follow Ken Mace:
About Alzheon: Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
CFO of Denali Therapeutics
Mr. Steve Krognes serves as Senior Vice President, Regional Head of Finance and IT and Chief Financial Officer of Pharma North America at Genentech, Inc. Mr. Krognes joined Roche in January 2004 as global head of Mergers and Acquisitions. He served as Head of Corporate Finance-Corporate Development of Roche Holding AG. In this role, he led Roche’s internal Mergers and Acquisitions group and was responsible for all Roche transactions worldwide. Prior to joining Roche Holding AG, Mr. Krognes worked as a venture capitalist in Scandinavia, as a mergers and acquisitions investment banker with Goldman Sachs and Danske Bank, and as a management consultant with McKinsey & Co. He has been a Director of California Healthcare Institute since August 2010. He is a second lieutenant in the Royal Norwegian Air Force. Mr. Krognes holds a Master’s in Business Administration from the Harvard Business School and a Bachelor’s in Economics from the Wharton School at the University of Pennsylvania.
Follow Steve Krognes:
About California Healthcare Institute, Denali Therapeutics: Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Chief Financial Officer of Horizon Discovery
Richard has over 15 years’ experience as a chartered accountant, working with life science companies from start-ups to global pharmaceuticals. He also has a first class degree in biological sciences from Durham University. Past roles include Vice President, Finance at CSR plc, a listed hi-tech company with revenues of $1bn. During his time at CSR Richard had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of a NASDAQ listed Zoran Corp., product portfolio management, R&D budgeting and business investment / divestment decisions. Before this, Richard was a Director in Deloitte’s life sciences practice, where he specialized in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets. Beyond his corporate responsibilities, Richard has advised the EC on funding for life science companies and presented at investor conferences and technical seminars on financial issues facing the life science industry.
Follow Richard Vellacott:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Olivia K. Bloom
CFO, Treasurer & EVP of Geron
Olivia K. Bloom is the chief financial officer, treasurer, and executive vice president of [Geron](https://www.crunchbase.com/organization/geron-corp#/entity), a biopharmaceutical company that discovers and develops therapeutic products for cancer. Before joining Geron, she started her career in public accounting at KPMG Peat Marwick and became a certified public accountant in 1994. Bloom holds a bachelor’s degree in business administration from the University of California, Berkeley.
Follow Olivia K. Bloom:
About Geron: Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel,
Chief Financial Officer of 98point6
Angelo Gray is the Chief Financial Officer of 98point6.
Follow Angelo Gray:
About 98point6: 98point6 is a digital primary care service that provides personalized consultation, diagnosis, and treatment to patients.
Chief Financial Officer of Kipu Health
Edmundo Aja is the Chief Financial Officer at Kipu Systems.
Follow Edmundo Aja:
About Kipu Health: SaaS platform for behavioral health and addiction treatment centers providing EHR, patient engagement and RCM solutions.
Chief Financial Officer of Exagen
Follow Kamal Adawi:
About Exagen: Exagen is a patient focused, discovery-driven life science company serving patients affected by autoimmune rheumatic diseases.
CFO of True Diagnostics
David Larson is CFO at True Diagnostics.
Follow David Larson:
About True Diagnostics: True Diagnostics is a research, development, and manufacturing company specialized in immunodiagnostic test systems.
COO, CFO, Founder of RadSupport, Inc.
Follow Roy Hess:
About RadSupport, Inc.: Deep Learning Computer Aided Diagnosis
Chief Financial Officer & Internal Legal Counsel of Immunexpress
35 years experience – finance, legal, investment banking and investment, corporate advisory and business/industry development (HWC (SA), Deloittes, Hill Samuel, Macquarie Bank, AGL Ltd, NEVI Group (Nor), Management Board Huon Aquaculture Ltd (AU) for 18 years). Financed, developed IKEA in Queensland, Australia. Senior management and Board roles in South Africa, Australia, Scandinavia and the Netherlands.
Follow Stefan Hendriks:
About Immunexpress: Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders.
Co-Founder & CFO of Astarte Medical
Tammi Jantzen is the cofounder of Astarte Medical, a precision medicine company that utilizes software and predictive analytics to improve health outcomes during the first 1,000 days of life.
Follow Tammi Jantzen:
About Astarte Medical, Astarte Ventures, Kauffman Fellows: Astarte Medical is the only precision medicine company using software and predictive analytics to improve outcomes in the first 1000 days.
Chief Financial Officer of Precision Image Analysis
Tom Waiss is experienced in finance and accounting with over 30 years in the computer/software industry. He has developed and supported service strategies at Hewlett Packard, Compaq and Digital Equipment Corporation. Tom has experience building new business lines and consulting practices within these companies.
Follow Thomas Waiss:
About Precision Image Analysis, Precision Image Analysis: Precision Image Analysis provides an innovative remote image post-processing analysis service for use in diagnostic medical studies.
William J. Kelly
Chief Financial Officer of Exosome Diagnostics
Mr. Kelly has over 20 years of financial management experience, including 13 years leading growing, international, publicly traded life science companies. Prior to joining Exosome Diagnostics, Mr. Kelly served in executive positions such as Chief Financial Officer of RepliGen Corporation and Corporate Controller of Haemonetics. In such roles, Mr. Kelly oversaw corporate financial operations, including several successful acquisitions. Mr. Kelly began his financial career as an auditor at leading financial firms Deloitte & Touche and Ernst and Young. Mr. Kelly is a Certified Public Accountant who holds an M.S./M.B.A. from Northeastern University and a B.A. in psychology from the College of the Holy Cross.
Follow William J. Kelly:
About Deloitte, Exosome Diagnostics: Exosome Diagnostics develops and commercializes blood-based cancer molecular diagnostics for patient stratification and disease monitoring.
CFO & Co-Founder of Genetesis
Follow Chandan Srivastava:
About Genetesis: Genetesis is a rapidly growing medical imaging company leveraging data science and biomagnetism in the fight against cardiovascular disease
David A. Frank
Chief Financial Officer of AquaBounty Technologies
Follow David A. Frank:
About AquaBounty Technologies: AquaBounty Technologies is a biotechnology company that focuses on improving productivity in commercial aquaculture.
Chief Financial Officer of Ximedica
Follow Jeff Thomas:
About Ximedica: Ximedica is a fully integrated product development firm focused on bringing medical technologies from first concept to market launch.
Chief Financial Officer of Sense Neuro Diagnostics
Paul Gaitan is the Chief Financial Officer of Sense Neuro Diagnostics.
Follow Paul Gaitan:
About Haag-Streit USA, Sense Neuro Diagnostics: Sense Neuro Diagnostics is a developer of non-invasive medical devices for neurological conditions.
CFO of Forest Devices
Follow Steve Morrow:
About Forest Devices: Forest Devices is a medical device startup that develops a novel stroke screening device designed to detect early signs of stokes.
Todd J. Anderson
Chief Financial Officer of Triopsy Medical
Mr. Anderson has worked with Mr. Buscher for almost 20 years setting up and growing early-stage companies. He brings his extensive background in setting up systems and controls for start-up entities to the initial phase of financing and operational functions of 3DBiopsy.
Follow Todd J. Anderson:
About Triopsy Medical: 3DBiopsy is a medical device company that develops a comprehensive system intended to aid in the diagnosis and treatment of prostate cancer.
CFO & COO of Advanced Tear Diagnostics (ATD)
Follow Gene Wahnefried:
About Advanced Tear Diagnostics (ATD): Develops and markets a highly specialized point-of-care (POC) lab testing system.
CFO of CellDrop Biosciences
Peter Scott currently works as the CFO for CellDrop Biosciences.
Follow Peter Scott:
About CellDrop Biosciences: CellDrop Biosciences develops hydrogel-based point-of-care diagnostics and targeted biomaterial delivery technology.
COO and CFO of CDx Life
Tom has over 20 years of experience in financial and senior executive management from well known, publicly traded technology companies. He has worked as the CFO for Western Digital and as the CFO and COO for I/O Magic. Tom holds an MBA from Pepperdine University.
Follow Tom Gruber:
About CDx Life: MyDx (My Diagnostic) is the world’s first portable analyzer for everyone – a simple and affordable device.
Chief Financial Officer of Cognoptix
Michael Kaswan is the Chief Financial Officer at Cognoptix.
Follow Michael Kaswan:
About Cognoptix, Dune Medical Devices: Cognoptix develops non-invasive eye tests for the early diagnosis of alzheimer disease.
CFO of TeloRegen Inc.
Follow Dwight Foster:
About TeloRegen Inc.: TeloRegen Inc. (TeloRegen) is a biotech company with a published pending patent for a practical Telomere Therapy in regenerative medicine.